SB
BOLT icon

Samsara BioCapital’s Bolt Biotherapeutics BOLT Stock Holding History

Samsara BioCapital’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,830
Closed -$260K – 24
2025
Q3 		$260K Sell
48,830
-3,626
-7% -$20.1K 0.03% 25
2025
Q2 		$303K Sell
52,456
-2
-0% -$13 0.06% 27
2025
Q1 		$420K Hold
52,458
– – 0.07% 31
2024
Q4 		$561K Hold
52,458
– – 0.08% 37
2024
Q3 		$680K Hold
52,458
– – 0.13% 36
2024
Q2 		$787K Hold
52,458
– – 0.16% 32
2024
Q1 		$1.47M Hold
52,458
– – 0.23% 31
2023
Q4 		$1.18M Hold
52,458
– – 0.18% 32
2023
Q3 		$1.09M Hold
52,458
– – 0.33% 31
2023
Q2 		$1.34M Hold
52,458
– – 0.24% 34
2023
Q1 		$1.46M Hold
52,458
– – 0.3% 36
2022
Q4 		$1.36M Hold
52,458
– – 0.29% 36
2022
Q3 		$1.55M Hold
52,458
– – 0.36% 39
2022
Q2 		$2.14M Hold
52,458
– – 0.57% 32
2022
Q1 		$2.88M Buy
52,458
+15,585
+42% +$1.05M 0.72% 33
2021
Q4 		$3.61M Hold
36,873
– – 0.7% 28
2021
Q3 		$9.33M Hold
36,873
– – 1.46% 17
2021
Q2 		$11.4M Hold
36,873
– – 1.41% 18
2021
Q1 		$24.3M Buy
+36,873
New +$24M 4.48% 8

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital's BOLT Position: Q4 2025 in Review

Samsara BioCapital sold out of Bolt Biotherapeutics (BOLT) in Q4 2025, closing a stake of 48,830 shares — an estimated $260K sold.

Samsara BioCapital first reported a position in BOLT in Q1 2021 and held it in 19 quarters. The position peaked at $24.3M in Q1 2021. 21 funds tracked by Wall St. Rank hold BOLT as of Q4 2025.

  • Samsara BioCapital reported no remaining Bolt Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Samsara BioCapital sold 48,830 Bolt Biotherapeutics shares in Q4 2025, an estimated $260K.
  • Samsara BioCapital first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 19 quarters.
  • Samsara BioCapital's Bolt Biotherapeutics position peaked at $24.3M in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.